I am pleased that our article has raised awareness of the external quality assurance (EQA) schemes for genetic testing. The article was principally targeted at biochemistry laboratories rather than specialist genetics laboratories, and, although it was not our intention to provide a comprehensive list of EQA schemes available for tests of monogenic disorders, we had hoped to provide su¤cient information for those engaged in genetic testing to source an appropriate scheme. We note that several of the schemes listed under the European Molecular Genetics Quality Network (EMQN) in our article are now also available from UK NEQAS. However, for many of the tests that may be particularly useful for our colleagues in specialist biochemistry laboratories, EQA schemes are not available nationally, if indeed they are available at all.
With respect to error rates, the ¢gure quoted by us was taken directly from an article from the EMQN and was clearly a matter of concern to its members. Presumably they have used these data as a stimulus to improve the quality of genetic testing by encouraging participation in EQA schemes. Whilst the ¢gures quoted by Dr Ramsden for a more recent estimation of error rates are an improvement, one wonders what the error rates are for tests that currently do not have established national schemes.
Gordon Ferns Clinical and Molecular Diagnostics Laboratory Royal Surrey County Hospital Guildford GU2 7XX, UK

Interference caused by the contents of serum separator tubes in the Vitros CRP assay
We wish to comment on the study of Chang et al. 1 who report higher serum C-reactive protein (CRP) concentrations, using the Vitros CRP assay, in samples collected into gel separator tubes when compared with plain tubes. We also have studied the stability of CRP, using the DPC Immulite high-sensitivity CRP assay, in samples collected into plain glass tubes, EDTA tubes gel tubes and separated at 20 min (baseline) and 1h, 2 h, 8 h and 24 h. 2 In samples separated at baseline, measured CRP concentrations were signi¢cantly higher in gel tubes than in plain and EDTA tubes. Otherwise, there were no signi¢cant di¡erences between tube CRP concentrations at any time point. In gel tubes, CRP concentrations were signi¢cantly lower at 8 h and 24 h when compared with the sample separated at baseline. There were no signi¢cant di¡erences in CRP concentrations in samples taken into plain or EDTA tubes over 24 h.
These ¢ndings of higher baseline serum CRP concentrations in gel tubes compared with plain tubes are consistent with those of Chang et al. 1 We additionally report a signi¢cant decline in CRP concentrations in gel tubes by 8 h post sampling. 2 These ¢ndings of discrepant results from di¡erent collection tubes are similar to previous studies reporting the e¡ect of gel tubes on other analytes, including therapeutic drugs 3 and intact parathyroid hormone. 4 Serum CRP concentrations, often in the`conventional' reference range, have an important role in the evaluation of cardiovascular risk and are of prognostic value in acute coronary syndromes. 5 We therefore disagree with the assertion of Chang et al. that between-tube di¡erences in CRP concentrations are only of importance at high CRP concentrations and are unlikely to cause a problem in interpretation at lower CRP concentrations.
We suggest that these between-tube di¡erences are more likely to in£uence clinical interpretation of CRP at lower concentrations especially where CRP is used as an aid to assess cardiovascular risk evaluation and prognosis of acute coronary syndromes.
We report an intra-assay coe¤cient of variation of 3.36% at a CRP concentration of 10.7 mg/L, using the Immulite high-sensitivity CRP assay. However, there is an additional 8.8^10.1% variation (according to the sample tube type) and a 10.7% decline in CRP concentrations if gel tubes are used for sample collection. Such variability due to sample tube type could lead to potential misclassi¢cation of patients under evaluation for cardiovascular risk and acute coronary syndrome. 
Routine transferrin saturation measurements in liver clinic patients increases detection of hereditary haemochromatosis
The use of serum transferrin saturation (TFS), as described by Poullis et al. 1 as an initial screening test for genetic haemochromatosis (HH) in patients with a high risk of the disease con¢rms our own ¢ndings. 2 Over a number of years we have developed a targeted screening approach to detect HH in patients with early liver disease. The rationale for our programme is the initial screening with TFS for the iron overload phenotype in patients with a biochemical marker of liver disease [raised serum alanine aminotransferase (ALT) found in any routine biochemistry request] followed by genetic testing to identify the C282Y genotype in those patients so identi¢ed. Over a 29-month period, all routine samples sent to the laboratory for liver function tests that had a raised ALT (greater than 50 iu/L) were selected for TFS. If the TFS was greater than 55%, a further fasting TFS was requested. If the fasting TFS was greater than 50%, patients were invited to attend the haematology clinic for genetic testing and assessment of iron overload. From 8770 samples with raised ALT, 376 samples (5%) had a raised TFS. A fasting TFS was requested on all of these, 194 samples being obtained. Seventy patients had a raised fasting TFS and genetic testing was performed on 66 of these. There were 32 HFE C282Y homozygotes detected. Over the same period of time the laboratory had referred on clinical grounds alone, 68 gene tests from all other clinicians in the hospital. Only seven C282Y homozygotes were detected by these traditional clinical methods. Thus, the diagnostic yield from our study was 32/66 (48%) and 7/68 (10%) from traditional methods.
Targeted screening using a raised ALT and subsequent TFS is an e¡ective method for detecting C282Y homozygotes who are likely to be a¡ected by the disease, and is ¢ve times more successful at detecting C282Y homozygotes than traditional clinical methods. Our study also suggests that patients so identi¢ed are at an early stage of the disease before irreversible liver damaged has occurred. This is in contrast to the ¢ndings of Poullis et al. who screened patients attending a liver clinic (presumably at a later stage of the diagnostic process) and found that seven out of the 18 patients with mutations had established liver cirrhosis.
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